在哥伦比亚,单个中心的经验超过600个药物脱敏
Verónica Pardo-Manrique1,2, Luis Fernando Ramírez-Zuluaga2,3, Diana Lucia Silva-Espinosa2,3
1Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.
Frontiers in allergy
|September 16, 2024
概括
药物脱敏 (DD) 成功治疗了99.2%的药物过敏反应 (DHRs) 患者,使治疗能够继续. 这种安全有效的程序,特别是针对单克隆抗体,显著改善了患者的治疗结果.
科学领域:
- 临床免疫学临床免疫学
- 药理学 药理学是指药理学的学科.
- 过敏和免疫学 过敏和免疫学
背景情况:
- 药物过敏反应 (DHRs) 构成重大公共卫生问题,限制治疗选择,并需要替代,往往不太有效或更昂贵的治疗方法.
- 药物脱敏 (DD) 提供了管理DHR的关键干预措施,积极影响患者的预后和疾病管理.
研究的目的:
- 描述在第三级护理中心进行大量药物脱敏手术的经验和结果.
- 评估药物脱敏方案的安全性和有效性,对有DHR病史的患者进行评估.
主要方法:
- 进行了一项观察性,横截面和描述性研究.
- 包括患有DHR的患者,他们在2012年3月至2023年5月期间接受了标准化的机构DD协议.
- 收集了关于患者人口统计,罪祸首药物,反应类型和脱敏结果的数据.
主要成果:
- 二百四十一个患者接受了641个DD手术. 单克隆抗体 (34.4%),化疗剂 (21.6%),NSAID (18.2%) 和抗生素 (17.4%) 是最常见的药物类别.
- 过敏反应 (51.8%) 和皮肤症状 (44%) 是导致DD的主要临床表现. 1型内类型占主导地位 (78.3%).
- 在99.2%的手术中实现了对DD的总体耐受性,允许继续进行必要的治疗.
结论:
- 药物脱敏是一种安全,有效和有用的程序,用于管理DHR患者.
- 成功的DD允许管理关键药物,积极影响潜在疾病的过程.
- 该研究强调了DD协议在扩大药物过敏患者治疗选择方面的重要性.
相关概念视频
Desensitization and Tachyphylaxis
1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K
Drug Administration and Therapy Phases: Overview
416
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
416
Altered States of Awareness
162
Altered states of consciousness represent significant deviations from one's normal mental state. These deviations can range from subtle changes in awareness to profound transformations in perception, thought processes, and sensory experiences. Altered states of consciousness can be triggered by various factors, including drug use, meditation, hypnosis, illness, or even intense fatigue.
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
162
Drug Discovery: Overview
7.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.6K
Blind Procedures
10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
103
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
103


